Abstract
Percutaneous coronary intervention (PCI) is the main treatment for patients with severe coronary vascular stenosis. However, In-stent neo-atherosclerosis (ISNA) is an important clinical complication in patients after PCI, which is mainly caused by a persistent inflammatory response and endothelial insufficiency. In the cardiovascular field, magnesium-based scaffolds stand out due to their properties. Magnesium plays a key role in regulating cardiovascular physiology. Magnesium deficiency can promote endothelial cell dysfunction, which contributes to the formation of atherosclerosis. Since astragaloside IV (AS‑IV) has been proven to have potent cardioprotective effects, we asked whether high levels of magnesium cooperate with AS‑IV might have effects on endothelial function and ISNA. We performed in vitro experiments on endothelial cells. Being treated with different concentrations of magnesium or/and AS-IV, the cell growth and migration were detected by CCK-8 and wound healing assay, respectively. The pro-inflammatory factors tumor necrosis factor α (TNF-α) and interleukin 6 (IL-6), adhesion molecule vascular cell adhesion molecule-1 (VCAM-1), and NF-kB were determined by qRT-PCR, ELISA kits or western blot. Results showed that high magnesium and AS-IV improved endothelial function, including promoting cell migration and decreasing the content of TNF-α, IL-6, VCAM-1, and NF-kB. With the supplement of AS-IV, additive magnesium maintains cell proliferation, migration, and function of endothelial cells. In conclusion, these findings suggest that high magnesium and AS‑IV could improve vascular endothelial dysfunction. Early detection and treatment for neo-atherosclerosis may be of great clinical significance for improving stent implantation efficacy and long-term prognosis.
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1007%2Fs12013-024-01250-8/MediaObjects/12013_2024_1250_Fig1_HTML.png)
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1007%2Fs12013-024-01250-8/MediaObjects/12013_2024_1250_Fig2_HTML.png)
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1007%2Fs12013-024-01250-8/MediaObjects/12013_2024_1250_Fig3_HTML.png)
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1007%2Fs12013-024-01250-8/MediaObjects/12013_2024_1250_Fig4_HTML.png)
Similar content being viewed by others
Abbreviations
- AS‑IV:
-
Astragaloside IV
- CHD:
-
Coronary heart disease
- CVD:
-
Cardiovascular disease
- IL-6:
-
Interleukin 6
- ISNA:
-
In-stent neo-atherosclerosis
- ISR:
-
In-stent restenosis
- LST:
-
Late stent thrombosis
- PCI:
-
Percutaneous coronary intervention
- TNF-α:
-
Tumor necrosis factor α
- VCAM-1:
-
Vascular cell adhesion molecule-1
References
Fedele, G., Castiglioni, S., & Maier, J. A., et al. (2021). High magnesium and sirolimus on rabbit vascular cells-An in vitro proof of concept. Materials, 14, 1970.
Nusca, A., Viscusi, M. M., & Piccirillo, F., et al. (2022). In stent neo-atherosclerosis: Pathophysiology, clinical implications, prevention, and therapeutic approaches. Life, 12, 393.
Tan, Y. Q., Chen, H. W., & Li, J. (2020). Astragaloside IV: An effective drug for the treatment of cardiovascular diseases. Drug Design, Development and Therapy, 14, 3731–3746.
Liu, C., Chen, L., & Zhang, K., et al. (2022). Tailoring ZE21B alloy with nature-inspired extracellular matrix secreted by micro-patterned smooth muscle cells and endothelial cells to promote surface biocompatibility. International Journal of Molecular Sciences, 23, 3180.
Hou, Z., **ang, M., & Chen, N., et al. (2021). The biological responses and mechanisms of endothelial cells to magnesium alloy. Regenerative Biomaterials, 8, rbab017.
Almousa, L. A., Salter, A. M., & Castellanos, M., et al. (2022). The response of the human umbilical vein endothelial cell transcriptome to variation in magnesium concentration. Nutrients, 14, 3586.
Meng, P., Yang, R., & Jiang, F., et al. (2021). Molecular mechanism of astragaloside IV in improving endothelial dysfunction of cardiovascular diseases mediated by oxidative stress. Oxidative Medicine and Cellular Longevity, 2021, 8.
Yang, C., Pan, Q., & Ji, K., et al. (2023). Review on the protective mechanism of astragaloside IV against cardiovascular diseases. Frontiers in Pharmacology, 14, 1187910.
Simion, V., Zhou, H., & Pierce, J. B., et al. (2020). LncRNA VINAS regulates atherosclerosis by modulating NF-kappaB and MAPK signaling. JCI Insight, 5(21), 1–15.
Park, S. J., Kang, S. J., & Virmani, R., et al. (2012). In-stent neoatherosclerosis: A final common pathway of late stent failure. Journal of the American College of Cardiology, 59, 2051–2057.
Liu, M., & Dudley, S. C. (2020). Magnesium, oxidative stress, inflammation, and cardiovascular disease. Antioxidants, 9, 32.
Qi, H., Heise, S., & Zhou, J., et al. (2019). Electrophoretic deposition of bioadaptive drug delivery coatings on magnesium alloy for bone repair. ACS Applied Materials and Interfaces, 11, 8625–8634.
Maier, J. A., Castiglioni, S., & Locatelli, L., et al. (2021). Magnesium and inflammation: Advances and perspectives. Seminars in Cell and Developmental Biology, 115, 37–44.
Echeverry-Rendon, M., Echeverria, F., & Buikema, H., et al. (2022). Endothelial function after the exposition of magnesium degradation products. Biomaterials Advances, 134, 112693.
Ye, L., Zhang, C., & Duan, Q., et al. (2023). Association of magnesium depletion score with cardiovascular disease and its association with longitudinal mortality in patients with cardiovascular disease. Journal of the American Heart Association, 12(e030077), 1–11.
Murphy, C., Byrne, J., & Keogh, J. B., et al. (2021). The acute effect of magnesium supplementation on endothelial function: A randomized cross-over pilot study. International Journal of Environmental Research and Public Health, 18, 5303.
Locatelli, L., Fedele, G., & Castiglioni, S., et al. (2021). Magnesium deficiency induces lipid accumulation in vascular endothelial cells via oxidative stress-The potential contribution of EDF-1 and PPARgamma. International Journal of Molecular Sciences, 22, 1050.
Xu, Z., Zhou, H., & Zhang, Y., et al. (2023). Recent pharmacological advances in the treatment of cardiovascular events with astragaloside IV. Biomedicine and Pharmacotherapy, 168, 115752.
Zhao, F., Meng, Y., & Wang, Y., et al. (2022). Protective effect of Astragaloside IV on chronic intermittent hypoxia-induced vascular endothelial dysfunction through the calpain-1/SIRT1/AMPK signaling pathway. Frontiers in Pharmacology, 13, 920977.
Su, Y., Yin, X., & Huang, X. (2022). Astragaloside IV ameliorates sepsis-induced myocardial dysfunction by regulating NOX4/JNK/BAX pathway. Life Sciences, 310, 121123.
Leng, B., Tang, F., & Lu, M., et al. (2018). Astragaloside IV improves vascular endothelial dysfunction by inhibiting the TLR4/NF-κB signaling pathway. Life Sciences, 209, 111–121.
Lin, L. H., Lee, H. P., & Yeh, M. L. (2020). Characterization of a sandwich PLGA-gallic acid-PLGA coating on Mg alloy ZK60 for bioresorbable coronary artery stents. Materials, 13, 5538.
You, L., Fang, Z., & Shen, G., et al. (2019). Astragaloside IV prevents high glucoseinduced cell apoptosis and inflammatory reactions through inhibition of the JNK pathway in human umbilical vein endothelial cells. Molecular Medicine Reports, 19, 1603–1612.
Xu, L., Willumeit-Romer, R., & Luthringer-Feyerabend, B. J. C. (2019). Effect of magnesium-degradation products and hypoxia on the angiogenesis of human umbilical vein endothelial cells. Acta Biomaterialia, 98, 269–283.
Li, L., Zhuang, S., & Jiang, S. (2024). Muscone inhibits the progression of atherosclerotic plaques in mice aorta by inhibiting the NF-κB/p65 pathway. Biochemical and Biophysical Research Communications, 702, 149628.
Becker, L. & Holtmann D. (2024). Anti-inflammatory effects of α-humulene on the release of pro-inflammatory cytokines in lipopolysaccharide-induced THP-1 cells. Cell Biochemistry and Biophysics, 82. https://doi.org/10.1007/s12013-024-01235-7.
Thayse, K., Kindt, N., & Laurent, S. (2020). VCAM-1 target in non-invasive imaging for the detection of atherosclerotic plaques. Biology, 9(11), 1–22.
Cheng, W., Cui, C., & Liu, G., et al. (2023). NF-κB, a potential therapeutic target in cardiovascular diseases. Cardiovascular Drugs and Therapy, 37(3), 571–584.
Nie, Q., Zhu, L., & Zhang, L., et al. (2019). Astragaloside IV protects against hyperglycemia-induced vascular endothelial dysfunction by inhibiting oxidative stress and Calpain-1 activation. Life Sciences, 232, 116662.
Shao, X., Liu, Z., & Liu, S., et al. (2021). Astragaloside IV alleviates atherosclerosis through targeting circ_0000231/miR-135a-5p/CLIC4 axis in AS cell model in vitro. Molecular and Cellular Biochemistry, 476, 1783–1795.
Zhang, Y., Du, M., & Wang, J., et al. (2022). Astragaloside IV relieves atherosclerosis and hepatic steatosis via MAPK/NF-κB signaling pathway in LDLR-/- Mice. Frontiers in Pharmacology, 13, 828161.
Funding
This work was supported by the Shaanxi Provincial Department of Science and Technology (Grant numbers 2021JQ-738, 2021JM-549 and 2024JC-YBQN-0198), Education Department of Shaanxi Provincial Government (Grant number 21JK0606), Shaanxi Association for Science and Technology (Grant number 20200312). Author Hongfei Qi has received research support from Shaanxi University of Chinese Medicine.
Author information
Authors and Affiliations
Contributions
All authors contributed to the study conception and design. Material preparation, data collection and analysis were preformed by Hongfei Qi, Teng Ge, Kun Wang and **g Wang. The first draft of the manuscript was written by Hongfei Qi and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.
Corresponding authors
Ethics declarations
Conflict of Interest
The authors declare no competing interests.
Consent for Publication
All the authors agreed on the publication of this manuscript.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Qi, H., Ge, T., Wang, K. et al. Effect of High Magnesium and Astragaloside IV on Vascular Endothelial Cells. Cell Biochem Biophys (2024). https://doi.org/10.1007/s12013-024-01250-8
Accepted:
Published:
DOI: https://doi.org/10.1007/s12013-024-01250-8